| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 280, Issue 38, 32618-32624, September 23, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Program in Pharmacogenomics, Department of Pharmacology, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio 43210
As a primary target for opioid drugs and peptides, the mu opioid receptor (OPRM1) plays a key role in pain perception and addiction. Genetic variants of OPRM1 have been implicated in predisposition to drug addiction, in particular the single nucleotide polymorphism A118G, leading to an N40D substitution, with an allele frequency of 10–32%, and uncertain functions. We have measured allele-specific mRNA expression of OPRM1 in human autopsy brain tissues, using A118G as a marker. In 8 heterozygous samples measured, the A118 mRNA allele was 1.5–2.5-fold more abundant than the G118 allele. Transfection into Chinese hamster ovary cells of a cDNA representing only the coding region of OPRM1, carrying adenosine, guanosine, cytidine, and thymidine in position 118, resulted in 1.5-fold lower mRNA levels only for OPRM1-G118, and more than 10-fold lower OPRM1 protein levels, measured by Western blotting and receptor binding assay. After transfection and inhibition of transcription with actinomycin D, analysis of mRNA turnover failed to reveal differences in mRNA stability between A118 and G118 alleles, indicating a defect in transcription or mRNA maturation. These results indicate that OPRM1-G118 is a functional variant with deleterious effects on both mRNA and protein yield. Clarifying the functional relevance of polymorphisms associated with susceptibility to a complex disorder such as drug addiction provides a foundation for clinical association studies.
Received for publication, May 4, 2005 , and in revised form, July 20, 2005.
* This work was supported by National Institutes of Health Grant DA018744. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence should be addressed: 5072 Graves Hall, 333 W. 10th Ave.,Dept. of Pharmacology, The Ohio State University, Columbus, OH 43210. Tel.: 614292-5593; Fax: 614-292-7232; E-mail: address: sadee-1{at}medctr.osu.edu.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Bertolino, L. Fazio, G. Caforio, G. Blasi, A. Rampino, R. Romano, A. Di Giorgio, P. Taurisano, A. Papp, J. Pinsonneault, et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia Brain, October 1, 2008; (2008) awn248v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates PNAS, April 1, 2008; 105(13): 5277 - 5281.
|
|
|
|
 |
|
 R. F. Anton, G. Oroszi, S. O'Malley, D. Couper, R. Swift, H. Pettinati, and D. Goldman An Evaluation of {micro}-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence: Results From the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study Arch Gen Psychiatry, February 1, 2008; 65(2): 135 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, A. Bertolino, L. Fazio, G. Blasi, A. Rampino, R. Romano, M.-L. T. Lee, T. Xiao, A. Papp, D. Wang, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory PNAS, December 18, 2007; 104(51): 20552 - 20557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Marczak, Y. Jinsmaa, T. Li, S. D. Bryant, Y. Tsuda, Y. Okada, and L. H. Lazarus [N-Allyl-Dmt1]-Endomorphins Are {micro}-Opioid Receptor Antagonists Lacking Inverse Agonist Properties J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 374 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Ray and K. E. Hutchison Effects of Naltrexone on Alcohol Sensitivity and Genetic Moderators of Medication Response: A Double-blind Placebo-Controlled Study Arch Gen Psychiatry, September 1, 2007; 64(9): 1069 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Cirulli and D. B. Goldstein In vitro assays fail to predict in vivo effects of regulatory polymorphisms Hum. Mol. Genet., August 15, 2007; 16(16): 1931 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chakass, D. Philippe, E. Erdual, S. Dharancy, M. Malapel, C. Dubuquoy, X. Thuru, J. Gay, C. Gaveriaux-Ruff, P. Dubus, et al. {micro}-Opioid receptor activation prevents acute hepatic inflammation and cell death Gut, July 1, 2007; 56(7): 974 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Kreek and K. S. LaForge Stress Responsivity, Addiction, and a Functional Variant of the Human Mu-Opioid Receptor Gene Mol. Interv., April 1, 2007; 7(2): 74 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Barr, M. Schwandt, S. G. Lindell, S. A. Chen, D. Goldman, S. J. Suomi, J. D. Higley, and M. Heilig Association of a Functional Polymorphism in the {micro}-Opioid Receptor Gene With Alcohol Response and Consumption in Male Rhesus Macaques Arch Gen Psychiatry, March 1, 2007; 64(3): 369 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Margas, I. Zubkoff, H. G. Schuler, P. K. Janicki, and V. Ruiz-Velasco Modulation of Ca2+ Channels by Heterologously Expressed Wild-Type and Mutant Human {micro}-Opioid Receptors (hMORs) Containing the A118G Single-Nucleotide Polymorphism J Neurophysiol, February 1, 2007; 97(2): 1058 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Pinsonneault, A. C. Papp, and W. Sadee Allelic mRNA expression of X-linked monoamine oxidase a (MAOA) in human brain: dissection of epigenetic and genetic factors Hum. Mol. Genet., September 1, 2006; 15(17): 2636 - 2649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lee and R. F. Tyndale Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. J Psychopharmacol, July 1, 2006; 20(4 Suppl): 7 - 14. [Abstract] [PDF]
|
|
|
|
|
|
K. Drakenberg, A. Nikoshkov, M. C. Horvath, P. Fagergren, A. Gharibyan, K. Saarelainen, S. Rahman, I. Nylander, G. Bakalkin, J. Rajs, et al. From the Cover: {micro} Opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers PNAS, May 16, 2006; 103(20): 7883 - 7888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, X. Luo, H. R. Kranzler, J. Lappalainen, B.-Z. Yang, E. Krupitsky, E. Zvartau, and J. Gelernter Association between two {micro}-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence Hum. Mol. Genet., March 15, 2006; 15(6): 807 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Milne Gene Variant Suggests Link To Addiction Vulnerability Psychiatr News, November 4, 2005; 40(21): 28 - 28. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
